Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Retrospective Study to Evaluate Efficacy and Safety of Trabectedin (Yondelis) in Sarcoma Patients

Trial Profile

Retrospective Study to Evaluate Efficacy and Safety of Trabectedin (Yondelis) in Sarcoma Patients

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Feb 2019

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Bone cancer; Soft tissue sarcoma
  • Focus Therapeutic Use
  • Acronyms ReTraSarc
  • Most Recent Events

    • 30 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2018.
    • 30 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 19 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top